Alnylam Pharmaceuticals (NASDAQ:ALNY) Releases Quarterly Earnings Results, Misses Estimates By $0.03 EPS

Alnylam Pharmaceuticals (NASDAQ:ALNY) announced its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.03), Zacks reports. Alnylam Pharmaceuticals updated its FY 2025 guidance to EPS.

Alnylam Pharmaceuticals Price Performance

Alnylam Pharmaceuticals stock traded down $11.01 during trading hours on Friday, hitting $253.88. The stock had a trading volume of 216,108 shares, compared to its average volume of 663,616. The company has a debt-to-equity ratio of 31.64, a current ratio of 2.75 and a quick ratio of 2.69. The stock has a market capitalization of $32.75 billion, a price-to-earnings ratio of -96.90 and a beta of 0.35. Alnylam Pharmaceuticals has a 1-year low of $141.98 and a 1-year high of $304.39. The stock’s fifty day moving average is $254.03 and its two-hundred day moving average is $263.00.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 5,219 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total transaction of $1,309,864.62. Following the sale, the chief executive officer now directly owns 78,880 shares in the company, valued at $19,797,302.40. The trade was a 6.21 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CMO Pushkal Garg sold 52,592 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Monday, January 27th. The stock was sold at an average price of $285.00, for a total value of $14,988,720.00. Following the sale, the chief marketing officer now owns 11,989 shares in the company, valued at $3,416,865. This represents a 81.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 73,964 shares of company stock valued at $20,622,925. Insiders own 1.50% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently weighed in on ALNY shares. Barclays lifted their price target on Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the company an “overweight” rating in a research note on Friday, November 1st. Royal Bank of Canada restated an “outperform” rating and issued a $300.00 price objective on shares of Alnylam Pharmaceuticals in a report on Tuesday. Sanford C. Bernstein cut their price target on shares of Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating on the stock in a research note on Tuesday, January 7th. Wolfe Research lowered shares of Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a research note on Tuesday, November 12th. Finally, Scotiabank boosted their price target on shares of Alnylam Pharmaceuticals from $305.00 to $310.00 and gave the stock a “sector outperform” rating in a research note on Friday, November 1st. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and nineteen have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $299.87.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.